Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
马萨诸塞州沃尔瑟姆，2024年11月21日（GLOBE NEWSWIRE）——Upstream Bio, Inc.（纳斯达克股票代码：UPB）是一家临床阶段的公司，最初专注于严重呼吸系统疾病。该公司今天宣布，Upstream Bio首席执行官兰德·萨瑟兰将于2024年12月3日下午2点参加派珀·桑德勒第36届年度医疗保健会议的炉边谈话 .Et。
A live webcast of the presentation will be available under the "Events" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活动当天，将在公司网站 “投资者” 页面的 “活动” 选项卡下观看演讲的网络直播。网络直播的重播将在演示结束后的90天内在公司网站上存档。
About Upstream Bio
关于上游生物
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .
Upstream Bio是一家临床阶段的生物技术公司，开发炎症性疾病的治疗方法，最初的重点是严重的呼吸系统疾病。该公司正在开发verekitug，这是目前唯一已知的靶向胸腺基质淋巴生成素受体的拮抗剂。胸腺基质淋巴生成素是一种经过临床验证的炎症反应驱动因素，位于影响各种免疫介导疾病的多个信号级联的上游。该公司已将这种高效的单克隆抗体推进到单独的2期试验，用于使用鼻息肉治疗严重哮喘和慢性鼻窦炎，并计划启动慢性阻塞性肺病的开发。Upstream Bio的团队致力于最大限度地发挥verekitug的独特特性，以解决当今标准护理服务不足的患者大量未得到满足的需求。要了解更多信息，请访问。
CONTACT: Investor Contact:
Michael Gray
Chief Financial Officer and Chief Operating Officer
ir@upstreambio.com
Media Contact:
Teri Dahlman
Red House Communications
teri@redhousecomms.com
联系人：投资者联系人：
迈克尔·格雷
首席财务官兼首席运营官
ir@upstreambio.com
媒体联系人：
泰瑞·达尔曼
红屋通讯
teri@redhousecomms.com
